Compare EVCM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | PSNL |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | EVCM | PSNL |
|---|---|---|
| Price | $9.87 | $16.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $11.00 | ★ $15.44 |
| AVG Volume (30 Days) | 151.7K | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | 33.58 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $588,907,000.00 | $69,648,000.00 |
| Revenue This Year | $4.16 | $18.40 |
| Revenue Next Year | $4.89 | $33.63 |
| P/E Ratio | $90.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.21 | $4.96 |
| 52 Week High | $14.41 | $18.89 |
| Indicator | EVCM | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 51.30 |
| Support Level | $8.98 | $15.92 |
| Resistance Level | $12.52 | $16.39 |
| Average True Range (ATR) | 0.56 | 0.38 |
| MACD | 0.23 | -0.10 |
| Stochastic Oscillator | 100.00 | 34.50 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.